Community Series in Recent Advances in Potential Biomarkers for Rheumatic Diseases and in Cell-based Therapies in the Management of Inflammatory Rheumatic Diseases, volume II

Know about the book -

Community Series in Recent Advances in Potential Biomarkers for Rheumatic Diseases and in Cell-based Therapies in the Management of Inflammatory Rheumatic Diseases, volume II is written by Eric Toussirot and published by Frontiers Media SA. It's available with International Standard Book Number or ISBN identification 2832559069 (ISBN 10) and 9782832559062 (ISBN 13).

Inflammatory rheumatic diseases (IRD) constitute a wide spectrum of disorders encompassing inflammatory arthropathies, including rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS). It also includes connective tissue disorders, such as systemic lupus erythematosus (SLE), Sjögren's syndrome (SS) or systemic sclerosis (SSc). This highly heterogeneous group of conditions has multifactorial and not fully understood etiology and is characterized by the presence of persistent inflammation affecting primarily the musculoskeletal system and connective tissue. Disease progression ultimately leads to functional disability, premature mortality, as well as economic and social burdens. Rheumatoid arthritis and spondyloarthritis represent the most common inflammatory rheumatic diseases. The management of RA and other forms of IRD has dramatically changed in the last 20 years with the development of targeted therapeutic agents, namely biological disease modifying anti-rheumatic drugs (bDMARDs) and targeted synthetic disease modifying anti-rheumatic drugs (tsDMARDs). However, a substantial proportion of patients still exhibits an inadequate response, do not achieve remission, or develop side effects.